CTLA4 and metastatic melanoma: Since the approval of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) inhibitors for the treatment of metastatic melanoma in the United States in 2011, PD-1/L1 inhibitors have been used to treat over 20 other malignancies [6].